Vol 5, Supplement 2 (August 22, 2016): Translational Cancer Research

Editorial

Gut microbia dysbiosis in non-alcoholic fatty liver disease

Debra A. Guss, Smruti R. Mohanty

PDF Pages: S152-S155 Full Text (4118) COI Form Open Access

Metformin: a promising candidate for chemoprevention of colorectal tumor and its future

Tae Il Kim

PDF Pages: S156-S159 Full Text (4455) COI Form Open Access

Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components

Brandon J. Manley, James J. Hsieh

PDF Pages: S160-S165 Full Text (7778) COI Form Open Access

Adjuvant therapy in early-stage small-cell lung cancer: what’s new?

Antonio Rossi

PDF Pages: S166-S169 Full Text (3964) COI Form Open Access

Recent randomized trials on stage III lung cancer treatment

Chi-Fu Jeffrey Yang, Thomas A. D’Amico

PDF Pages: S170-S173 Full Text (3940) COI Form Open Access

“Switchable chimeric antigen receptor T cells: a novel universal chimeric antigen receptor platform for a safe control of T-cell activation”

Silvia Arcangeli, Chiara F. Magnani, Sarah Tettamanti, Ettore Biagi

PDF Pages: S174-S177 Full Text (8256) COI Form Open Access

Results of the REGATTA trial on surgical therapy of limited metastatic gastric cancer: open issues and future perspectives

Lena-Christin Conradi, Florian Lordick, Andreas Pircher

PDF Pages: S178-S181 Full Text (4602) Open Access

Towards prevention of metastatic prostate cancer: recent molecular insights from the direct analysis of metastatic precursor cells

Miodrag Gužvić, Christoph A. Klein

PDF Pages: S182-S186 Full Text (3641) COI Form Open Access

Genomic analysis of pancreatic cancer: a glimmer of hope for the therapy?

Simone Polvani, Andrea Galli

PDF Pages: S187-S191 Full Text (3818) COI Form Open Access

Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: fact or fiction?

Chen-Hua Liu, Jia-Horng Kao

PDF Pages: S192-S195 Full Text (4073) Open Access

The role of circadian clock genes in leukemia

Ming-Yu Yang, Sheng-Fung Lin

PDF Pages: S196-S198 Full Text (4502) COI Form Open Access

PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?

Yusuke Inoue, Murat Osman, Takafumi Suda, Haruhiko Sugimura

PDF Pages: S199-S202 Full Text (5282) COI Form Open Access

Positron emission tomography-CT surveillance versus neck dissection in advanced head and neck cancer: time for a paradigm shift in management

Jason I. Kass, Vikas Mehta

PDF Pages: S203-S204 Full Text (2670) COI Form Open Access

Exosomes as “translational” cancer promoter organelles

Isabella Panfoli

PDF Pages: S205-S207 Full Text (3215) COI Form Open Access

Trans-arterial embolization for hepatocellular carcinoma: with or without epidoxorubicin?

Alessandro Cucchetti, Alberta Cappelli, Rita Golfieri

PDF Pages: S208-S211 Full Text (3374) COI Form Open Access

Calculation of recurrence risk of ductal carcinoma in situ: open questions, controversies and future perspectives

Menelaos Zafrakas

PDF Pages: S212-S215 Full Text (11485) COI Form Open Access

Hepatitis B virus core-related antigen is a serum prediction marker for hepatocellular carcinoma

Kazunori Kawaguchi, Masao Honda, Shuichi Kaneko

PDF Pages: S216-S220 Full Text (3953) COI Form Open Access

Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy

Fabiana Perna, Michel Sadelain

PDF Pages: S221-S225 Full Text (9597) COI Form Open Access

Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells

Alex J. Gooding, William P. Schiemann

PDF Pages: S226-S232 Full Text (8376) COI Form Open Access

Tumor recurrence in patients treated with direct-acting antivirals for hepatitis C following curative therapy: a cause for concern?

Sevan Evren, David K. H. Wong

PDF Pages: S233-S236 Full Text (3356) COI Form Open Access

Promise of vandetanib, a FDA-approved RET kinase inhibitor, for the treatment of RET fusion-positive lung adenocarcinoma

Takashi Kohno

PDF Pages: S237-S239 Full Text (4691) COI Form Open Access

Pazopanib: a new therapeutic option for advanced gastrointestinal stromal tumors

George Z. Li, Chandrajit P. Raut

PDF Pages: S240-S242 Full Text (3340) COI Form Open Access

Actionable intelligence provided by pancreatic cancer genomic landscape: are targets for curative therapy on the map?

Nathan A. Berger

PDF Pages: S243-S247 Full Text (4791) COI Form Open Access

GD3 mediated immune response via vascular endothelial growth factor in ovarian cancer

Aristotle Bamias, Nikos G. Gavalas

PDF Pages: S248-S252 Full Text (3429) COI Form Open Access

HNF1A, KRT81, and CYP3A5: three more straws on the back of pancreatic cancer?

Andrew J. Scott, John C. Wilkinson

PDF Pages: S253-S256 Full Text (5061) COI Form Open Access

Functional and clinical impact of MYC mutations in diffuse large B cell lymphomas

Nathalie A. Johnson

PDF Pages: S257-S260 Full Text (4318) COI Form Open Access

Long-term use of sunitinib in metastatic renal cell carcinoma: no unpleasant surprises about tolerability

Constance Michel, Constance Thibault, Stephane Oudard

PDF Pages: S261-S263 Full Text (4505) COI Form Open Access

TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?

Derek B. Oien, Jeremy Chien

PDF Pages: S264-S268 Full Text (7146) COI Form Open Access

Crucial role of vascular endothelial growth factor in the immune system of patients with ovarian cancer

Yasuto Kinose, Kenjiro Sawada, Tadashi Kimura

PDF Pages: S269-S271 Full Text (3403) COI Form Open Access

Perspective

Perspective on the EF-14 trial and its implications for the role of tumor-treating fields in the management of glioblastoma

Suyash Mohan, Sanjeev Chawla, Aaron Skolnik, Harish Poptani

PDF Pages: S272-S275 Full Text (5452) COI Form Open Access

Multimodality treatment in limited small cell lung cancer (L-SCLC): different perspectives about the optimal approach

Valentina Polo, Giulia Pasello

PDF Pages: S276-S281 Full Text (3944) COI Form Open Access

Emerging molecular pathways and targets in neuroendocrine prostate cancer

M. Francesca Monn, Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng

PDF Pages: S282-S285 Full Text (3438) COI Form Open Access

Novel non-invasive urine-based gene expression assay discriminates between low- and high-risk prostate cancer before biopsy

Malte W. Vetterlein, Quoc-Dien Trinh, Felix K. H. Chun

PDF Pages: S286-S289 Full Text (3643) Open Access

Benefits, limitations and opportunities of NOTCH inhibitors for treatment of glioma

Sanaz Yahyanejad, Patrick V. Granton, Ann Hoeben, Marc A. Vooijs

PDF Pages: S290-S295 Full Text (4389) COI Form Open Access

Commentary

Tumor-associated neutrophils: an emerging player in the immune microenvironment of hepatocellular carcinoma

Li-Chun Lu, Chih-Hung Hsu

PDF Pages: S296-S299 Full Text (4507) COI Form Open Access

The expanding role of exosomes in cancer biology and therapy

Edward Sauter

PDF Pages: S300-S302 Full Text (3173) COI Form Open Access

Tumor-infiltrating T cells are invigorated by modulating cholesterol metabolism

Erica L. Stone, Louise M. D’Cruz

PDF Pages: S303-S305 Full Text (4087) COI Form Open Access

Epidermal growth factor receptor-tyrosine kinase inhibitors, which is the best choice?

Tetsuya Oguri

PDF Pages: S306-S308 Full Text (2689) Open Access

CCR5 antagonist, an ally to fight against metastatic colorectal cancer

Naofumi Mukaida

PDF Pages: S309-S312 Full Text (5903) COI Form Open Access

Interleukin-2 as anticancer immunotherapy in the age of checkpoint inhibition

Claus Garbe

PDF Pages: S313-S314 Full Text (3366) COI Form Open Access

Chimeric antigen receptor T cells get passed by leukemia

Frederick L. Locke, Marco L. Davila

PDF Pages: S315-S317 Full Text (4603) Open Access

Pancreatic ductal adenocarcinoma—a new hope?

Glen R. B. Irving, Dileep N. Lobo

PDF Pages: S318-S320 Full Text (2901) COI Form Open Access

Urinary exosome and beyond

Yu-Ru Liu, Yi-Fen Lee

PDF Pages: S321-S324 Full Text (3524) COI Form Open Access

Immunoscore vs. Microsatellite instability as prognostic biomarkers in colorectal cancer: who wins?

Constantin N. Baxevanis

PDF Pages: S325-S327 Full Text (4106) COI Form Open Access

Divergent roles of miR-126 in normal and malignant stem cells

Harold K. Elias, Mona Khalaj, Christopher Y. Park

PDF Pages: S328-S331 Full Text (3181) COI Form Open Access

Treatment improvement by addition of leucovorin to S-1 plus oxaliplatin in patients with advanced gastric cancer

Aziz Zaanan, Simon Pernot, Julien Taieb

PDF Pages: S332-S334 Full Text (3070) COI Form Open Access

p-21 activated kinase 4 (PAK4) role in pancreatic cancer stem cells

Marta Herreros-Villanueva, Luis Bujanda

PDF Pages: S335-S337 Full Text (3034) COI Form Open Access

Helios—controller of Treg stability and function

Claire Chougnet, David Hildeman

PDF Pages: S338-S341 Full Text (7153) COI Form Open Access

Dabrafenib in patients with BRAF-mutated non-small cell lung cancer

Takahisa Kawamura, Haruyasu Murakami

PDF Pages: S342-S344 Full Text (4311) COI Form Open Access

Deep sequencing reveals that low level TP53 mutations are ubiquitous in ovarian cancer patients and controls: successes and challenges for early detection

Hugues Sicotte

PDF Pages: S345-S348 Full Text (3332) COI Form Open Access

Sweetening of glutamine metabolism in cancer cells by Rho GTPases through convergence of multiple oncogenic signaling pathways

Thambi Dorai, John T. Pinto, Arthur J. L. Cooper

PDF Pages: S349-S356 Full Text (5253) COI Form Open Access

CRISPR/Cas9 engineering offers new opportunities to model pancreatic ductal adenocarcinoma development

Claus Jørgensen, Elizabeth K. J. Hogg

PDF Pages: S357-S359 Full Text (3167) COI Form Open Access

An instructive ductal microenvironment is key for efficient in vivo modeling of estrogen receptor positive breast cancer

Kristopher A. Lofgren, Paraic A. Kenny

PDF Pages: S360-S362 Full Text (2695) COI Form Open Access

Correspondence

Elucidating alternative pathways triggering small cell lung carcinoma tumor biology

Lydia Meder, Reinhard Buettner

PDF Pages: S363-S365 Full Text (3143) COI Form Open Access

CCR5 inhibition in colorectal cancer patients

Niels Halama

PDF Pages: S366-S367 Full Text (3594) Open Access

Immuno-molecular characterization of colorectal cancer tumors and its clinical implications

Etienne Becht, Catherine Sautès-Fridman, Aurélien de Reyniès, Wolf-Herman Fridman

PDF Pages: S368-S370 Full Text (3536) COI Form Open Access

ESOGIA: a “first step” for comprehensive geriatric assessment-guided treatment in non-small cell lung cancer

Romain Corre, Christos Chouaïd

PDF Pages: S371-S373 Full Text (3031) Open Access

Long journey to prevent metachronous gastric cancer after endoscopic resection

Jiro Watari, Maki Kawanaka, Toshihiko Tomita, Tadayuki Oshima, Hirokazu Fukui, Kiron M. Das, Hiroto Miwa

PDF Pages: S374-S376 Full Text (2694) COI Form Open Access

Concurrent or sequential letrozole with adjuvant breast radiotherapy: primetime for personalized radiation oncology

Celine Bourgier, David Azria

PDF Pages: S377-S379 Full Text (3223) COI Form Open Access

Disclosure:

This supplement was published without any sponsorship or funding.